A Genomics Driven Pluripotent Stem Cell Model of Infant Lymphoblastic Leukemia |
Children's Mercy Hospital Kansas City / Meagan Vacek, DO |
Catalyst Grants |
2023 |
Missouri |
Mutagenesis and disease progression in RUNX1 mutant blood stem cells is caused by inflammation-induced hyperactive signaling and supraphysiological mitochondrial ROS |
St. Jude Children’s Research Hospital / Dirk Loeffler, PhD |
RUNX1 Early Career Investigator Grants |
2023 |
Tennessee |
Creating an Infrastructure for Collaborative Clinical Research and Publication of Consensus Guidelines for RUNX1 Familial Platelet Disorder |
The Cleveland Clinic Foundation / Brittany Stewart, PhD |
RUNX1 Early Career Investigator Grants |
2023 |
Ohio |
Synthetic gene expression regulator switches (SynGERS) expressed in CAR T cells to cure children with solid tumors |
Baylor College of Medicine / Andras Heczey, MD |
R Accelerated Award Grants |
2023 |
Texas |
CLL-1 CAR-T cells with or without trametinib for the treatment of JMML |
The Regents of the University of California San Francisco / Elliot Stieglitz, MD |
R Accelerated Award Grants |
2023 |
California |
Activation of Anti-Leukemia Immunity by Targeting Protein Arginine Methyltransferase |
City of Hope National Medical Center / Ling Li, PhD |
R Accelerated Award Grants |
2023 |
California |
Development of New Approaches to Target MAP Kinase Pathway in RAS-driven Rhabdomyosarcoma |
University of Texas Health Science Center at San Antonio / Angelina Vaseva, PhD |
R Accelerated Award Grants |
2023 |
Texas |
The role of pyruvate kinase as a therapeutic target in pediatric leukemia |
Rutgers Cancer Institute of New Jersey / Daniel Herranz Benito, PhD |
R Accelerated Award Grants |
2023 |
New Jersey |